Physician profile
Ryan H Phan
NPI 1588027213
$4,940.97
in general payments reported to CMS, 2019-2025
13 companies · $246 in 2025
The $246 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $145 · 2021: $708 · 2022: $668 · 2023: $522 · 2024: $2,652 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,720 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,720.37 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,700.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,193.28 | 2020-2025 | Hydrus Microstent, Eysuvis |
| Abbvie INC. | $891.88 | 2022-2025 | |
| Glaukos Corporation | $343.23 | 2020-2024 | Idose, Istent Trabecular Micro-Bypass System Model Is3 |
| Sight Sciences, INC. | $332.92 | 2022-2024 | Omni Surgical System |
| Aerie Pharmaceuticals, INC. | $265.84 | 2020-2021 | |
| Bausch & Lomb Americas INC. | $245.87 | 2022-2024 | Totalvisc |
| Allergan, INC. | $230.36 | 2021-2022 | |
| Ivantis, INC | $148.39 | 2021 | |
| Amgen INC. | $127.43 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $80.51 | 2022-2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $32.91 | 2024 | Xdemvy |
| Oyster Point Pharma, INC. | $26.53 | 2023 | Tyrvaya |
| Rxsight INC | $21.82 | 2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Phan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.